Author:
Mohammed Shaimaa M.,Al-Saedi Haider Falih Shamikh,Mohammed Amjed Qasim,Amir Ahmed Ali,Radi Usama Kadem,Sattar Ruaa,Ahmad Irfan,Ramadan Montather F.,Alshahrani Mohammad Y.,Balasim Halah Majeed,Alawadi Ahmed
Funder
Deanship of Scientific Research, King Khalid University
Publisher
Springer Science and Business Media LLC
Reference258 articles.
1. Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022). Cancer statistics, 2022. CA: Cancer Journal for Clinicians, 72, 7–33.
2. Moslehi, M., Moazamiyanfar, R., Dakkali, M. S., Rezaei, S., Rastegar-Pouyani, N., Jafarzadeh, E., Mouludi, K., Khodamoradi, E., Taeb, S., & Najafi, M. (2022). Modulation of the immune system by melatonin; Implications for cancer therapy. International Immunopharmacology, 108, 108890. https://doi.org/10.1016/j.intimp.2022.108890.
3. Agrawal, S. (2014). Late effects of cancer treatment in breast cancer survivors. South Asian Journal of Cancer, 3, 112–115.
4. Laprise-Lachance, M., Lemieux, P., & Grégoire, J.-P. (2019). Risk of pulmonary toxicity of bleomycin and filgrastim. Journal of Oncology Pharmacy Practice, 25, 1638–1644.
5. Zorzi, A. P., Yang, C. L., Dell, S., & Nathan, P. C. (2015). Bleomycin-associated lung toxicity in childhood cancer survivors. Journal of Pediatric Hematology/Oncology, 37, e447–e452.